Cybin partners with worldwide clinical trials to support future clinical development of cyb003 in major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment option, today announced that it has partnered with worldwide clinical trials (“worldwide”), a global, full-service contract research organization (“cro”) with deep expertise managing clinical trials for mental health conditions, including major depressive disorder. to.
CYBN Ratings Summary
CYBN Quant Ranking